FPHAX — Select Pharmaceuticals Portfolio
Data updated: 2026-07-24
FPHAX — Select Pharmaceuticals Portfolio. Global (incl. US) Large Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
FPHAX Fund Overview
FPHAX — Select Pharmaceuticals Portfolio is a US mutual fund managed by Fidelity Select Portfolios, categorised as Global (incl. US) Large Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Select Portfolios
- Category: Global (incl. US) Large Cap Blend / Core Health Care Equity
- Assets under management: $1.50B
- 1-year return: 44.6%
- Ticker: FPHAX
- SEC CIK: 0000320351
- SEC series ID: S000007481
- Share class ID: C000020455
FPHAX Holdings
Top 10 holdings of Select Pharmaceuticals Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| ELI LILLY and CO | 28.78% |
| Gsk PLC | 8.17% |
| Viatris, Inc. | 5.45% |
| Ucb SA | 5.09% |
| MERCK and CO INC | 4.74% |
| Roche Holding AG | 4.54% |
| Legend Biotech Corp. | 4.53% |
| Astrazeneca PLC | 4.22% |
| Elanco Animal Health, Inc. | 4.15% |
| Jazz Pharmaceuticals PLC | 4.09% |
FPHAX Portfolio Allocation
Asset-class allocation of Select Pharmaceuticals Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.4% |
| Cash & Equivalents | 2.6% |
| Fixed Income | 0.1% |
FPHAX Performance
Total returns for FPHAX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 9.1% |
| 1 year | 44.6% |
| 3 years (annualised) | 18.5% |
| 5 years (annualised) | 13.2% |
FPHAX Risk Information
Risk metrics for FPHAX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.0%
FPHAX Costs and Fees
FPHAX costs about $67 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.67%
- Gross expense ratio: 0.67%
- Portfolio turnover: 77%
- Brokerage commissions: 5.24 bps of average net assets (SEC N-CEN)
FPHAX Cashflows
Over the 12 months to 2026-05, Select Pharmaceuticals Portfolio had net inflows of $12.06M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-05 | −$5.24M |
| 2026-04 | $16.56M |
| 2026-03 | −$9.07M |
| 2026-02 | $8.43M |
| 2026-01 | $48.18M |
| 2025-12 | $66.93M |
FPHAX Debt Constituents
Largest debt holdings of Select Pharmaceuticals Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Evozyne, Inc. | 0.08% |
FPHAX Prospectus and SEC Filings
Official Select Pharmaceuticals Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-04-24
- Prospectus (485BPOS) — filed 2025-04-24
- Prospectus (485BPOS) — filed 2024-04-24
- Portfolio holdings (N-PORT) — filed 2026-07-24
- Portfolio holdings (N-PORT) — filed 2026-04-24
- Portfolio holdings (N-PORT) — filed 2026-01-23
- Annual census (N-CEN) — filed 2026-05-12
- Annual census (N-CEN) — filed 2025-05-13
Related Funds
Other Global (incl. US) Large Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.